245 related articles for article (PubMed ID: 33508385)
1. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
Bourn JR; Ruiz-Torres SJ; Hunt BG; Benight NM; Waltz SE
Cancer Lett; 2021 Apr; 503():75-90. PubMed ID: 33508385
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.
Ruiz-Torres SJ; Bourn JR; Benight NM; Hunt BG; Lester C; Waltz SE
Oncogene; 2022 Jan; 41(3):321-333. PubMed ID: 34743208
[TBL] [Abstract][Full Text] [Related]
3. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
4. Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression.
Sullivan C; Brown NE; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
Mol Cancer Res; 2020 Aug; 18(8):1244-1254. PubMed ID: 32439702
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.
Johnson AL; Zinser GM; Waltz SE
Oncotarget; 2015 Jun; 6(18):16304-20. PubMed ID: 26008979
[TBL] [Abstract][Full Text] [Related]
7. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
8. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.
Png KJ; Halberg N; Yoshida M; Tavazoie SF
Nature; 2011 Dec; 481(7380):190-4. PubMed ID: 22170610
[TBL] [Abstract][Full Text] [Related]
9. HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.
Benight NM; Wagh PK; Zinser GM; Peace BE; Stuart WD; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
Oncotarget; 2015 Jul; 6(19):17445-61. PubMed ID: 25938541
[TBL] [Abstract][Full Text] [Related]
10. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.
Cunha S; Lin YC; Goossen EA; DeVette CI; Albertella MR; Thomson S; Mulvihill MJ; Welm AL
Cell Rep; 2014 Jan; 6(1):141-54. PubMed ID: 24388747
[TBL] [Abstract][Full Text] [Related]
11. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
12. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
13. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.
Kato A; Ng S; Thangasamy A; Han H; Zhou W; Raeppel S; Fallon M; Guha S; Ammanamanchi S
Mol Carcinog; 2021 Nov; 60(11):734-745. PubMed ID: 34347914
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.
Marshall AM; McClaine RJ; Gurusamy D; Gray JK; Lewnard KE; Khan SA; Waltz SE
Mol Cancer; 2012 Jan; 11():2. PubMed ID: 22226043
[TBL] [Abstract][Full Text] [Related]
15. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
Feres KJ; Ischenko I; Hayman MJ
Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
17. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
Kretschmann KL; Eyob H; Buys SS; Welm AL
Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
[TBL] [Abstract][Full Text] [Related]
19. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
20. The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity.
Wilson CB; Ray M; Lutz M; Sharda D; Xu J; Hankey PA
J Immunol; 2008 Aug; 181(4):2303-10. PubMed ID: 18684919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
